The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Cancer Antibody Drug Conjugates Market Research Report 2025
Synopsis
The global Cancer Antibody Drug Conjugates market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Cancer Antibody Drug Conjugates is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Cancer Antibody Drug Conjugates is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Cancer Antibody Drug Conjugates include Novartis, Merck, Roche, AbbVie, UCB, Bristol-Myers Squibb, Stem CentRx, Biogen Idec and Nordic Nanovector, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Cancer Antibody Drug Conjugates, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Antibody Drug Conjugates.
Report Scope
The Cancer Antibody Drug Conjugates market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cancer Antibody Drug Conjugates market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cancer Antibody Drug Conjugates manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Merck
Roche
AbbVie
UCB
Bristol-Myers Squibb
Stem CentRx
Biogen Idec
Nordic Nanovector
Millennium
Biotest AG
PDL BioPharma
Progenics Pharmaceuticals
Seattle Genetics
Viventia Biotechnologies
AbGenomics Corporation
Helix BioPharma
Segment by Type
First & Second Generation ADCs
Third Generation ADCs
Segment by Application
Hospitals
Clinics
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Cancer Antibody Drug Conjugates manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Cancer Antibody Drug Conjugates in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Cancer Antibody Drug Conjugates market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Cancer Antibody Drug Conjugates is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Cancer Antibody Drug Conjugates is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Cancer Antibody Drug Conjugates include Novartis, Merck, Roche, AbbVie, UCB, Bristol-Myers Squibb, Stem CentRx, Biogen Idec and Nordic Nanovector, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Cancer Antibody Drug Conjugates, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Antibody Drug Conjugates.
Report Scope
The Cancer Antibody Drug Conjugates market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cancer Antibody Drug Conjugates market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cancer Antibody Drug Conjugates manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Merck
Roche
AbbVie
UCB
Bristol-Myers Squibb
Stem CentRx
Biogen Idec
Nordic Nanovector
Millennium
Biotest AG
PDL BioPharma
Progenics Pharmaceuticals
Seattle Genetics
Viventia Biotechnologies
AbGenomics Corporation
Helix BioPharma
Segment by Type
First & Second Generation ADCs
Third Generation ADCs
Segment by Application
Hospitals
Clinics
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Cancer Antibody Drug Conjugates manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Cancer Antibody Drug Conjugates in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Cancer Antibody Drug Conjugates Market Overview
1.1 Product Overview and Scope of Cancer Antibody Drug Conjugates
1.2 Cancer Antibody Drug Conjugates Segment by Type
1.2.1 Global Cancer Antibody Drug Conjugates Market Value Comparison by Type (2024-2030)
1.2.2 First & Second Generation ADCs
1.2.3 Third Generation ADCs
1.3 Cancer Antibody Drug Conjugates Segment by Application
1.3.1 Global Cancer Antibody Drug Conjugates Market Value by Application: (2024-2030)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Cancer Antibody Drug Conjugates Market Size Estimates and Forecasts
1.4.1 Global Cancer Antibody Drug Conjugates Revenue 2019-2030
1.4.2 Global Cancer Antibody Drug Conjugates Sales 2019-2030
1.4.3 Global Cancer Antibody Drug Conjugates Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Cancer Antibody Drug Conjugates Market Competition by Manufacturers
2.1 Global Cancer Antibody Drug Conjugates Sales Market Share by Manufacturers (2019-2024)
2.2 Global Cancer Antibody Drug Conjugates Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Cancer Antibody Drug Conjugates Average Price by Manufacturers (2019-2024)
2.4 Global Cancer Antibody Drug Conjugates Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Cancer Antibody Drug Conjugates, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Cancer Antibody Drug Conjugates, Product Type & Application
2.7 Cancer Antibody Drug Conjugates Market Competitive Situation and Trends
2.7.1 Cancer Antibody Drug Conjugates Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Cancer Antibody Drug Conjugates Players Market Share by Revenue
2.7.3 Global Cancer Antibody Drug Conjugates Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Cancer Antibody Drug Conjugates Retrospective Market Scenario by Region
3.1 Global Cancer Antibody Drug Conjugates Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Cancer Antibody Drug Conjugates Global Cancer Antibody Drug Conjugates Sales by Region: 2019-2030
3.2.1 Global Cancer Antibody Drug Conjugates Sales by Region: 2019-2024
3.2.2 Global Cancer Antibody Drug Conjugates Sales by Region: 2025-2030
3.3 Global Cancer Antibody Drug Conjugates Global Cancer Antibody Drug Conjugates Revenue by Region: 2019-2030
3.3.1 Global Cancer Antibody Drug Conjugates Revenue by Region: 2019-2024
3.3.2 Global Cancer Antibody Drug Conjugates Revenue by Region: 2025-2030
3.4 North America Cancer Antibody Drug Conjugates Market Facts & Figures by Country
3.4.1 North America Cancer Antibody Drug Conjugates Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Cancer Antibody Drug Conjugates Sales by Country (2019-2030)
3.4.3 North America Cancer Antibody Drug Conjugates Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Cancer Antibody Drug Conjugates Market Facts & Figures by Country
3.5.1 Europe Cancer Antibody Drug Conjugates Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Cancer Antibody Drug Conjugates Sales by Country (2019-2030)
3.5.3 Europe Cancer Antibody Drug Conjugates Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Cancer Antibody Drug Conjugates Market Facts & Figures by Country
3.6.1 Asia Pacific Cancer Antibody Drug Conjugates Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Cancer Antibody Drug Conjugates Sales by Country (2019-2030)
3.6.3 Asia Pacific Cancer Antibody Drug Conjugates Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Cancer Antibody Drug Conjugates Market Facts & Figures by Country
3.7.1 Latin America Cancer Antibody Drug Conjugates Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Cancer Antibody Drug Conjugates Sales by Country (2019-2030)
3.7.3 Latin America Cancer Antibody Drug Conjugates Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Cancer Antibody Drug Conjugates Market Facts & Figures by Country
3.8.1 Middle East and Africa Cancer Antibody Drug Conjugates Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Cancer Antibody Drug Conjugates Sales by Country (2019-2030)
3.8.3 Middle East and Africa Cancer Antibody Drug Conjugates Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Cancer Antibody Drug Conjugates Sales by Type (2019-2030)
4.1.1 Global Cancer Antibody Drug Conjugates Sales by Type (2019-2024)
4.1.2 Global Cancer Antibody Drug Conjugates Sales by Type (2025-2030)
4.1.3 Global Cancer Antibody Drug Conjugates Sales Market Share by Type (2019-2030)
4.2 Global Cancer Antibody Drug Conjugates Revenue by Type (2019-2030)
4.2.1 Global Cancer Antibody Drug Conjugates Revenue by Type (2019-2024)
4.2.2 Global Cancer Antibody Drug Conjugates Revenue by Type (2025-2030)
4.2.3 Global Cancer Antibody Drug Conjugates Revenue Market Share by Type (2019-2030)
4.3 Global Cancer Antibody Drug Conjugates Price by Type (2019-2030)
5 Segment by Application
5.1 Global Cancer Antibody Drug Conjugates Sales by Application (2019-2030)
5.1.1 Global Cancer Antibody Drug Conjugates Sales by Application (2019-2024)
5.1.2 Global Cancer Antibody Drug Conjugates Sales by Application (2025-2030)
5.1.3 Global Cancer Antibody Drug Conjugates Sales Market Share by Application (2019-2030)
5.2 Global Cancer Antibody Drug Conjugates Revenue by Application (2019-2030)
5.2.1 Global Cancer Antibody Drug Conjugates Revenue by Application (2019-2024)
5.2.2 Global Cancer Antibody Drug Conjugates Revenue by Application (2025-2030)
5.2.3 Global Cancer Antibody Drug Conjugates Revenue Market Share by Application (2019-2030)
5.3 Global Cancer Antibody Drug Conjugates Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Corporation Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Novartis Cancer Antibody Drug Conjugates Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Merck
6.2.1 Merck Corporation Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Merck Cancer Antibody Drug Conjugates Product Portfolio
6.2.5 Merck Recent Developments/Updates
6.3 Roche
6.3.1 Roche Corporation Information
6.3.2 Roche Description and Business Overview
6.3.3 Roche Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Roche Cancer Antibody Drug Conjugates Product Portfolio
6.3.5 Roche Recent Developments/Updates
6.4 AbbVie
6.4.1 AbbVie Corporation Information
6.4.2 AbbVie Description and Business Overview
6.4.3 AbbVie Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2019-2024)
6.4.4 AbbVie Cancer Antibody Drug Conjugates Product Portfolio
6.4.5 AbbVie Recent Developments/Updates
6.5 UCB
6.5.1 UCB Corporation Information
6.5.2 UCB Description and Business Overview
6.5.3 UCB Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2019-2024)
6.5.4 UCB Cancer Antibody Drug Conjugates Product Portfolio
6.5.5 UCB Recent Developments/Updates
6.6 Bristol-Myers Squibb
6.6.1 Bristol-Myers Squibb Corporation Information
6.6.2 Bristol-Myers Squibb Description and Business Overview
6.6.3 Bristol-Myers Squibb Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Bristol-Myers Squibb Cancer Antibody Drug Conjugates Product Portfolio
6.6.5 Bristol-Myers Squibb Recent Developments/Updates
6.7 Stem CentRx
6.6.1 Stem CentRx Corporation Information
6.6.2 Stem CentRx Description and Business Overview
6.6.3 Stem CentRx Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Stem CentRx Cancer Antibody Drug Conjugates Product Portfolio
6.7.5 Stem CentRx Recent Developments/Updates
6.8 Biogen Idec
6.8.1 Biogen Idec Corporation Information
6.8.2 Biogen Idec Description and Business Overview
6.8.3 Biogen Idec Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Biogen Idec Cancer Antibody Drug Conjugates Product Portfolio
6.8.5 Biogen Idec Recent Developments/Updates
6.9 Nordic Nanovector
6.9.1 Nordic Nanovector Corporation Information
6.9.2 Nordic Nanovector Description and Business Overview
6.9.3 Nordic Nanovector Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Nordic Nanovector Cancer Antibody Drug Conjugates Product Portfolio
6.9.5 Nordic Nanovector Recent Developments/Updates
6.10 Millennium
6.10.1 Millennium Corporation Information
6.10.2 Millennium Description and Business Overview
6.10.3 Millennium Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Millennium Cancer Antibody Drug Conjugates Product Portfolio
6.10.5 Millennium Recent Developments/Updates
6.11 Biotest AG
6.11.1 Biotest AG Corporation Information
6.11.2 Biotest AG Cancer Antibody Drug Conjugates Description and Business Overview
6.11.3 Biotest AG Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Biotest AG Cancer Antibody Drug Conjugates Product Portfolio
6.11.5 Biotest AG Recent Developments/Updates
6.12 PDL BioPharma
6.12.1 PDL BioPharma Corporation Information
6.12.2 PDL BioPharma Cancer Antibody Drug Conjugates Description and Business Overview
6.12.3 PDL BioPharma Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2019-2024)
6.12.4 PDL BioPharma Cancer Antibody Drug Conjugates Product Portfolio
6.12.5 PDL BioPharma Recent Developments/Updates
6.13 Progenics Pharmaceuticals
6.13.1 Progenics Pharmaceuticals Corporation Information
6.13.2 Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Description and Business Overview
6.13.3 Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Product Portfolio
6.13.5 Progenics Pharmaceuticals Recent Developments/Updates
6.14 Seattle Genetics
6.14.1 Seattle Genetics Corporation Information
6.14.2 Seattle Genetics Cancer Antibody Drug Conjugates Description and Business Overview
6.14.3 Seattle Genetics Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Seattle Genetics Cancer Antibody Drug Conjugates Product Portfolio
6.14.5 Seattle Genetics Recent Developments/Updates
6.15 Viventia Biotechnologies
6.15.1 Viventia Biotechnologies Corporation Information
6.15.2 Viventia Biotechnologies Cancer Antibody Drug Conjugates Description and Business Overview
6.15.3 Viventia Biotechnologies Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Viventia Biotechnologies Cancer Antibody Drug Conjugates Product Portfolio
6.15.5 Viventia Biotechnologies Recent Developments/Updates
6.16 AbGenomics Corporation
6.16.1 AbGenomics Corporation Corporation Information
6.16.2 AbGenomics Corporation Cancer Antibody Drug Conjugates Description and Business Overview
6.16.3 AbGenomics Corporation Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2019-2024)
6.16.4 AbGenomics Corporation Cancer Antibody Drug Conjugates Product Portfolio
6.16.5 AbGenomics Corporation Recent Developments/Updates
6.17 Helix BioPharma
6.17.1 Helix BioPharma Corporation Information
6.17.2 Helix BioPharma Cancer Antibody Drug Conjugates Description and Business Overview
6.17.3 Helix BioPharma Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Helix BioPharma Cancer Antibody Drug Conjugates Product Portfolio
6.17.5 Helix BioPharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Cancer Antibody Drug Conjugates Industry Chain Analysis
7.2 Cancer Antibody Drug Conjugates Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Cancer Antibody Drug Conjugates Production Mode & Process
7.4 Cancer Antibody Drug Conjugates Sales and Marketing
7.4.1 Cancer Antibody Drug Conjugates Sales Channels
7.4.2 Cancer Antibody Drug Conjugates Distributors
7.5 Cancer Antibody Drug Conjugates Customers
8 Cancer Antibody Drug Conjugates Market Dynamics
8.1 Cancer Antibody Drug Conjugates Industry Trends
8.2 Cancer Antibody Drug Conjugates Market Drivers
8.3 Cancer Antibody Drug Conjugates Market Challenges
8.4 Cancer Antibody Drug Conjugates Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Cancer Antibody Drug Conjugates Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Cancer Antibody Drug Conjugates Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Cancer Antibody Drug Conjugates Market Competitive Situation by Manufacturers in 2023
Table 4. Global Cancer Antibody Drug Conjugates Sales (K Dose) of Key Manufacturers (2019-2024)
Table 5. Global Cancer Antibody Drug Conjugates Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Cancer Antibody Drug Conjugates Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Cancer Antibody Drug Conjugates Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Cancer Antibody Drug Conjugates Average Price (USD/Dose) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Cancer Antibody Drug Conjugates, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Cancer Antibody Drug Conjugates, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Cancer Antibody Drug Conjugates, Product Type & Application
Table 12. Global Key Manufacturers of Cancer Antibody Drug Conjugates, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Cancer Antibody Drug Conjugates by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Antibody Drug Conjugates as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Cancer Antibody Drug Conjugates Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Cancer Antibody Drug Conjugates Sales by Region (2019-2024) & (K Dose)
Table 18. Global Cancer Antibody Drug Conjugates Sales Market Share by Region (2019-2024)
Table 19. Global Cancer Antibody Drug Conjugates Sales by Region (2025-2030) & (K Dose)
Table 20. Global Cancer Antibody Drug Conjugates Sales Market Share by Region (2025-2030)
Table 21. Global Cancer Antibody Drug Conjugates Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Cancer Antibody Drug Conjugates Revenue Market Share by Region (2019-2024)
Table 23. Global Cancer Antibody Drug Conjugates Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Cancer Antibody Drug Conjugates Revenue Market Share by Region (2025-2030)
Table 25. North America Cancer Antibody Drug Conjugates Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Cancer Antibody Drug Conjugates Sales by Country (2019-2024) & (K Dose)
Table 27. North America Cancer Antibody Drug Conjugates Sales by Country (2025-2030) & (K Dose)
Table 28. North America Cancer Antibody Drug Conjugates Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Cancer Antibody Drug Conjugates Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Cancer Antibody Drug Conjugates Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Cancer Antibody Drug Conjugates Sales by Country (2019-2024) & (K Dose)
Table 32. Europe Cancer Antibody Drug Conjugates Sales by Country (2025-2030) & (K Dose)
Table 33. Europe Cancer Antibody Drug Conjugates Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Cancer Antibody Drug Conjugates Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Cancer Antibody Drug Conjugates Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Cancer Antibody Drug Conjugates Sales by Region (2019-2024) & (K Dose)
Table 37. Asia Pacific Cancer Antibody Drug Conjugates Sales by Region (2025-2030) & (K Dose)
Table 38. Asia Pacific Cancer Antibody Drug Conjugates Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Cancer Antibody Drug Conjugates Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Cancer Antibody Drug Conjugates Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Cancer Antibody Drug Conjugates Sales by Country (2019-2024) & (K Dose)
Table 42. Latin America Cancer Antibody Drug Conjugates Sales by Country (2025-2030) & (K Dose)
Table 43. Latin America Cancer Antibody Drug Conjugates Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Cancer Antibody Drug Conjugates Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Cancer Antibody Drug Conjugates Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Cancer Antibody Drug Conjugates Sales by Country (2019-2024) & (K Dose)
Table 47. Middle East & Africa Cancer Antibody Drug Conjugates Sales by Country (2025-2030) & (K Dose)
Table 48. Middle East & Africa Cancer Antibody Drug Conjugates Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Cancer Antibody Drug Conjugates Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Cancer Antibody Drug Conjugates Sales (K Dose) by Type (2019-2024)
Table 51. Global Cancer Antibody Drug Conjugates Sales (K Dose) by Type (2025-2030)
Table 52. Global Cancer Antibody Drug Conjugates Sales Market Share by Type (2019-2024)
Table 53. Global Cancer Antibody Drug Conjugates Sales Market Share by Type (2025-2030)
Table 54. Global Cancer Antibody Drug Conjugates Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Cancer Antibody Drug Conjugates Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Cancer Antibody Drug Conjugates Revenue Market Share by Type (2019-2024)
Table 57. Global Cancer Antibody Drug Conjugates Revenue Market Share by Type (2025-2030)
Table 58. Global Cancer Antibody Drug Conjugates Price (USD/Dose) by Type (2019-2024)
Table 59. Global Cancer Antibody Drug Conjugates Price (USD/Dose) by Type (2025-2030)
Table 60. Global Cancer Antibody Drug Conjugates Sales (K Dose) by Application (2019-2024)
Table 61. Global Cancer Antibody Drug Conjugates Sales (K Dose) by Application (2025-2030)
Table 62. Global Cancer Antibody Drug Conjugates Sales Market Share by Application (2019-2024)
Table 63. Global Cancer Antibody Drug Conjugates Sales Market Share by Application (2025-2030)
Table 64. Global Cancer Antibody Drug Conjugates Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Cancer Antibody Drug Conjugates Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Cancer Antibody Drug Conjugates Revenue Market Share by Application (2019-2024)
Table 67. Global Cancer Antibody Drug Conjugates Revenue Market Share by Application (2025-2030)
Table 68. Global Cancer Antibody Drug Conjugates Price (USD/Dose) by Application (2019-2024)
Table 69. Global Cancer Antibody Drug Conjugates Price (USD/Dose) by Application (2025-2030)
Table 70. Novartis Corporation Information
Table 71. Novartis Description and Business Overview
Table 72. Novartis Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 73. Novartis Cancer Antibody Drug Conjugates Product
Table 74. Novartis Recent Developments/Updates
Table 75. Merck Corporation Information
Table 76. Merck Description and Business Overview
Table 77. Merck Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 78. Merck Cancer Antibody Drug Conjugates Product
Table 79. Merck Recent Developments/Updates
Table 80. Roche Corporation Information
Table 81. Roche Description and Business Overview
Table 82. Roche Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 83. Roche Cancer Antibody Drug Conjugates Product
Table 84. Roche Recent Developments/Updates
Table 85. AbbVie Corporation Information
Table 86. AbbVie Description and Business Overview
Table 87. AbbVie Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 88. AbbVie Cancer Antibody Drug Conjugates Product
Table 89. AbbVie Recent Developments/Updates
Table 90. UCB Corporation Information
Table 91. UCB Description and Business Overview
Table 92. UCB Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 93. UCB Cancer Antibody Drug Conjugates Product
Table 94. UCB Recent Developments/Updates
Table 95. Bristol-Myers Squibb Corporation Information
Table 96. Bristol-Myers Squibb Description and Business Overview
Table 97. Bristol-Myers Squibb Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 98. Bristol-Myers Squibb Cancer Antibody Drug Conjugates Product
Table 99. Bristol-Myers Squibb Recent Developments/Updates
Table 100. Stem CentRx Corporation Information
Table 101. Stem CentRx Description and Business Overview
Table 102. Stem CentRx Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 103. Stem CentRx Cancer Antibody Drug Conjugates Product
Table 104. Stem CentRx Recent Developments/Updates
Table 105. Biogen Idec Corporation Information
Table 106. Biogen Idec Description and Business Overview
Table 107. Biogen Idec Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 108. Biogen Idec Cancer Antibody Drug Conjugates Product
Table 109. Biogen Idec Recent Developments/Updates
Table 110. Nordic Nanovector Corporation Information
Table 111. Nordic Nanovector Description and Business Overview
Table 112. Nordic Nanovector Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 113. Nordic Nanovector Cancer Antibody Drug Conjugates Product
Table 114. Nordic Nanovector Recent Developments/Updates
Table 115. Millennium Corporation Information
Table 116. Millennium Description and Business Overview
Table 117. Millennium Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 118. Millennium Cancer Antibody Drug Conjugates Product
Table 119. Millennium Recent Developments/Updates
Table 120. Biotest AG Corporation Information
Table 121. Biotest AG Description and Business Overview
Table 122. Biotest AG Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 123. Biotest AG Cancer Antibody Drug Conjugates Product
Table 124. Biotest AG Recent Developments/Updates
Table 125. PDL BioPharma Corporation Information
Table 126. PDL BioPharma Description and Business Overview
Table 127. PDL BioPharma Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 128. PDL BioPharma Cancer Antibody Drug Conjugates Product
Table 129. PDL BioPharma Recent Developments/Updates
Table 130. Progenics Pharmaceuticals Corporation Information
Table 131. Progenics Pharmaceuticals Description and Business Overview
Table 132. Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 133. Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Product
Table 134. Progenics Pharmaceuticals Recent Developments/Updates
Table 135. Seattle Genetics Corporation Information
Table 136. Seattle Genetics Description and Business Overview
Table 137. Seattle Genetics Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 138. Seattle Genetics Cancer Antibody Drug Conjugates Product
Table 139. Seattle Genetics Recent Developments/Updates
Table 140. Viventia Biotechnologies Corporation Information
Table 141. Viventia Biotechnologies Description and Business Overview
Table 142. Viventia Biotechnologies Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 143. Viventia Biotechnologies Cancer Antibody Drug Conjugates Product
Table 144. Viventia Biotechnologies Recent Developments/Updates
Table 145. AbGenomics Corporation Corporation Information
Table 146. AbGenomics Corporation Description and Business Overview
Table 147. AbGenomics Corporation Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 148. AbGenomics Corporation Cancer Antibody Drug Conjugates Product
Table 149. AbGenomics Corporation Recent Developments/Updates
Table 150. Helix BioPharma Corporation Information
Table 151. Helix BioPharma Description and Business Overview
Table 152. Helix BioPharma Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 153. Helix BioPharma Cancer Antibody Drug Conjugates Product
Table 154. Helix BioPharma Recent Developments/Updates
Table 155. Key Raw Materials Lists
Table 156. Raw Materials Key Suppliers Lists
Table 157. Cancer Antibody Drug Conjugates Distributors List
Table 158. Cancer Antibody Drug Conjugates Customers List
Table 159. Cancer Antibody Drug Conjugates Market Trends
Table 160. Cancer Antibody Drug Conjugates Market Drivers
Table 161. Cancer Antibody Drug Conjugates Market Challenges
Table 162. Cancer Antibody Drug Conjugates Market Restraints
Table 163. Research Programs/Design for This Report
Table 164. Key Data Information from Secondary Sources
Table 165. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Cancer Antibody Drug Conjugates
Figure 2. Global Cancer Antibody Drug Conjugates Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Cancer Antibody Drug Conjugates Market Share by Type in 2023 & 2030
Figure 4. First & Second Generation ADCs Product Picture
Figure 5. Third Generation ADCs Product Picture
Figure 6. Global Cancer Antibody Drug Conjugates Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Cancer Antibody Drug Conjugates Market Share by Application in 2023 & 2030
Figure 8. Hospitals
Figure 9. Clinics
Figure 10. Others
Figure 11. Global Cancer Antibody Drug Conjugates Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Cancer Antibody Drug Conjugates Market Size (2019-2030) & (US$ Million)
Figure 13. Global Cancer Antibody Drug Conjugates Sales (2019-2030) & (K Dose)
Figure 14. Global Cancer Antibody Drug Conjugates Average Price (USD/Dose) & (2019-2030)
Figure 15. Cancer Antibody Drug Conjugates Report Years Considered
Figure 16. Cancer Antibody Drug Conjugates Sales Share by Manufacturers in 2023
Figure 17. Global Cancer Antibody Drug Conjugates Revenue Share by Manufacturers in 2023
Figure 18. The Global 5 and 10 Largest Cancer Antibody Drug Conjugates Players: Market Share by Revenue in 2023
Figure 19. Cancer Antibody Drug Conjugates Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 20. Global Cancer Antibody Drug Conjugates Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 21. North America Cancer Antibody Drug Conjugates Sales Market Share by Country (2019-2030)
Figure 22. North America Cancer Antibody Drug Conjugates Revenue Market Share by Country (2019-2030)
Figure 23. U.S. Cancer Antibody Drug Conjugates Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Canada Cancer Antibody Drug Conjugates Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Europe Cancer Antibody Drug Conjugates Sales Market Share by Country (2019-2030)
Figure 26. Europe Cancer Antibody Drug Conjugates Revenue Market Share by Country (2019-2030)
Figure 27. Germany Cancer Antibody Drug Conjugates Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. France Cancer Antibody Drug Conjugates Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. U.K. Cancer Antibody Drug Conjugates Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Italy Cancer Antibody Drug Conjugates Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Russia Cancer Antibody Drug Conjugates Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Asia Pacific Cancer Antibody Drug Conjugates Sales Market Share by Region (2019-2030)
Figure 33. Asia Pacific Cancer Antibody Drug Conjugates Revenue Market Share by Region (2019-2030)
Figure 34. China Cancer Antibody Drug Conjugates Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Japan Cancer Antibody Drug Conjugates Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. South Korea Cancer Antibody Drug Conjugates Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. India Cancer Antibody Drug Conjugates Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Australia Cancer Antibody Drug Conjugates Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Taiwan Cancer Antibody Drug Conjugates Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Indonesia Cancer Antibody Drug Conjugates Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Thailand Cancer Antibody Drug Conjugates Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Malaysia Cancer Antibody Drug Conjugates Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Philippines Cancer Antibody Drug Conjugates Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Latin America Cancer Antibody Drug Conjugates Sales Market Share by Country (2019-2030)
Figure 45. Latin America Cancer Antibody Drug Conjugates Revenue Market Share by Country (2019-2030)
Figure 46. Mexico Cancer Antibody Drug Conjugates Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Brazil Cancer Antibody Drug Conjugates Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Argentina Cancer Antibody Drug Conjugates Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Middle East & Africa Cancer Antibody Drug Conjugates Sales Market Share by Country (2019-2030)
Figure 50. Middle East & Africa Cancer Antibody Drug Conjugates Revenue Market Share by Country (2019-2030)
Figure 51. Turkey Cancer Antibody Drug Conjugates Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Saudi Arabia Cancer Antibody Drug Conjugates Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. U.A.E Cancer Antibody Drug Conjugates Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. Global Sales Market Share of Cancer Antibody Drug Conjugates by Type (2019-2030)
Figure 55. Global Revenue Market Share of Cancer Antibody Drug Conjugates by Type (2019-2030)
Figure 56. Global Cancer Antibody Drug Conjugates Price (USD/Dose) by Type (2019-2030)
Figure 57. Global Sales Market Share of Cancer Antibody Drug Conjugates by Application (2019-2030)
Figure 58. Global Revenue Market Share of Cancer Antibody Drug Conjugates by Application (2019-2030)
Figure 59. Global Cancer Antibody Drug Conjugates Price (USD/Dose) by Application (2019-2030)
Figure 60. Cancer Antibody Drug Conjugates Value Chain
Figure 61. Cancer Antibody Drug Conjugates Production Process
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Distributors Profiles
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
